So incredibly proud of the hard work from the JAB lab and especially for recent PhD graduate Omar Osorio leading the charge on this exciting work just published online in JCI Insight! insight.jci.org/articles/view/…
Jen A-Brett
@jablab3.bsky.social
Jen A-Brett MD PhD ATSF | 🫁 transplant & critical care | mechanisms of epithelial-immune crosstalk | cytokines & EVs in airway disease | #extracellularlife | Twitter @jablab3
There are no words adequate to express the gratitude I feel for those who contributed to and supported me through this effort. It’s the product of their talent, fortitude, guidance and belief that made it possible. Especially @tombrettlab and countless others who will hear from me in due time ❤️🙏🥂
What can I say, I work with an amazing group of thoughtful, supportive and talented people, who also enjoy birthdays 🙏🙏🙏
From 2010 to 2016 (latest data I have ), NIH research contributed to EVERY drug approved by the FDA
If you think DOGE has created massive inefficiencies and waste in their activities to date, and you live in the state of MO, you might want to flood their portal with your comments:
Right about now wondering how many Trump voters work at Universities in: Facilities Management Environmental Services Construction/renovation projects (including steel workers, HVAC, electrical, plumbing, painters) Large equipment installation or repair Security IT Need I go on…..
Jen A-Brett@jablab3.bsky.social · 2y agoWait, what????
Pleased to share our latest work now posted on @biorxivpreprint.bsky.social www.biorxiv.org/content/10.1...
HSP70 is a chaperone for IL-33 secretion and function in chronic airway disease
Rationale IL-33 is a key driver of type 2 inflammation relevant to airway epithelial biology. However, the mechanisms for IL-33 secretion and regulation in the context of chronic airway disease is poo...
biorxiv.org
I am so thrilled to share our latest collab with @jablab3.bsky.social ! Structural mapping of #TREM2 ligand interactions by #BLI. Led by Jessica Greven; thanks to big contributions by Josh Wydra, Cynthia Zhi,... molecularneurodegeneration.biomedcentral.com/articles/10....
Biophysical mapping of TREM2-ligand interactions reveals shared surfaces for engagement of multiple Alzheimer’s disease ligands - Molecular Neurodegeneration
TREM2 is a signaling receptor expressed on microglia that has emerged as an important drug target for Alzheimer’s disease and other neurodegenerative diseases. While a number of TREM2 ligands have bee...
molecularneurodegeneration.biomedcentral.com
Check out the latest from our groups on TREM2, driven by rockstar postbac Jess Greven and @tombrettlab.bsky.social! @washumedicine.bsky.social doi.org/10.1186/s130...
Biophysical mapping of TREM2-ligand interactions reveals shared surfaces for engagement of multiple Alzheimer’s disease ligands - Molecular Neurodegeneration
TREM2 is a signaling receptor expressed on microglia that has emerged as an important drug target for Alzheimer’s disease and other neurodegenerative diseases. While a number of TREM2 ligands have bee...
doi.org
My bluebirds flocking to the feeders in the fresh snow, the BEST biscuits, and a new Spotify playlist (JAB Classical). The unit tomorrow, but today is a good day 💙
You know how the emails pile up over the holidays, and when you clean your inbox out by quick screen/delete, you hope you didn't get rid of something important? Just found out we @jablab3.bsky.social had a big paper accepted a week ago because the notice got deleted. Happy discoveries!
a person is typing on a keyboard with the words deleting delete intensifies
ALT: a person is typing on a keyboard with the words deleting delete intensifies
media.tenor.com
So excited to have our new paper out now! Pyroptotic EVs “transplant” gasdermin pores from dying cells onto bystander cells, propagating pyroptosis and inflammation. t.co/XgU6jt15aF 1/3 #innate_immunity #immunoSky #celldeath #ExtracellularVesicles @uconnresearch.bsky.social
Photo credit in image, I NEED to see this bird that is reportedly in the area.
Ok, finally a science post for BlueSky: Check out our latest editorial in @TheJHLT, strong work as always from Ghandi (@Ghandi_Hassan_ on X) www.sciencedirect.com/science/arti...
Harnessing Mesenchymal Stem Cells for Improving Lung Transplant Outcomes
sciencedirect.com
Time to wait out the soufflé cheesecake, this spot will do 😊
Isn’t it amazing that when bullying behavior happens to others, it’s easy to give advice and guidance. But when it happens to you, it’s hard to figure out what to do in the moment.
Some know I have a thing for making playlists, but top 4% worldwide? Ok 🤣 If you wanna check them out Jen AB on @Spotify sites.wustl.edu/jablab (we all know the winner is @Hozier)
#PCCMSky Update 146 members- only 4 more slots in this starter pack Repost so the noobs know who the cool PCCM kids are Reply if you are not included and should be (make sure your creds are in your bio I am not putting randos on here) go.bsky.app/88wg6oG
"If talent and opportunity were equally distributed, the average winner would come from a middle income background. The reality? The average laureate grew up in a household just below the top 10%. More than 50% come from the top 5%" By Torsten Bell www.theguardian.com/commentisfre...
The science behind winning a Nobel Prize? Being a man from a wealthy family | Torsten Bell
A lot of talent is wasted in a world where more than half of laureates come from households in the richest 5%
theguardian.com
He doesn’t get it. That’s ok. Fellow karaoke enthusiasts IYKYK ❤️ 🎤
Tracey Thorn@traceythorn.bsky.social · 2y agoBobby Gillespie in today’s Guardian, “I don’t think I’ve ever done karaoke. I hate hearing people murder songs.” 👀
Interesting riff on science inspired by a story about Chappell Roan. I like it. Equally good food for those: 1) quietly struggling to find the motivation to keep going with their science 2) ignorantly raging about the process and taxpayer value of science www.instagram.com/reel/DCjzrMJ...
This is very interesting. And it DOES NOT mean that TREM2 is not a good target. It's a complex target.
Shannon Macauley@macauleylab.bsky.social · 2y agoAlector announced that its investigational agent AL002, a TREM2-targeting therapy, did not meet primary, secondary, or exploratory end points in the phase 2 INVOKE-2 trial (NCT04592874) in early AD. company is stopping the long-term extension study.1 www.neurologylive.com/view/al002-f...